Page 15 - 南京医科大学自然版

第46卷第8期 兰 欣，韩国勇，吴金道. 靶向联合免疫方案结合或不结合TACE/放疗在中晚期肝细胞癌转化治疗中
2026年8月 的应用［J］. 南京医科大学学报（自然科学版），2026，46（8）：1113-1121 ·1121 ·

tectomy following conversion therapy：a multicenter retro⁃ （GUIDANCE003）：a multicenter study［J］. Liver Cancer，
spective study［J］. Front Immunol，2024，15：1308543 2025，14（6）：687-703
［16］QUAN B，DAI M R，ZHANG P L，et al. Automating classi⁃ ［25］HATANAKA T，KAKIZAKI S，HIRAOKA A，et al. Pre⁃
fication of treatment responses to combined targeted therapy dictive factors and survival outcome of conversion therapy
and immunotherapy in HCC［J］. J Mol Cell Biol，2026，17 for unresectable hepatocellular carcinoma patients receiv⁃
（7）：mjaf031 ing atezolizumab and bevacizumab：comparative analysis of
［17］LIN S R，SONG Z M，CHEN P Z，et al. Conversion therapy conversion，partial response and complete response pa⁃
based on TACE/HAIC ⁃ based treatment to improve the tients［J］. Aliment Pharmacol Ther，2024，60（10）：1361-
therapeutic effect of initially unresectable hepatocellular 1373
carcinoma［J］. Liver Cancer，2026，15（2）：254-284 ［26］XU B，ZHU X D，SHEN Y H，et al. Criteria for identifying
［18］PAN Y X，WANG X H，PENG C，et al. Hepatic arterial potentially resectable patients with initially oncologically
infusionchemotherapyplussintilimabasconversiontherapy unresectable hepatocellular carcinoma before treatment
for locally advanced hepatocellular carcinoma：a single⁃ with lenvatinib plus an anti⁃PD⁃1 antibody［J］. Front Im⁃
center phase Ⅱ trial［J］. Int J Surg，2026，112（4）：9753- munol，2022，13：1016736
9760 ［27］TANG H W，ZHANG W W，CAO J N，et al. Chinese ex⁃
［19］WU X K，YANG L F，CHEN Y F，et al. Transcatheter pert consensus on sequential surgery following conversion
arterial chemoembolisation combined with lenvatinib plus therapy based on combination of immune checkpoint in⁃
camrelizumab as conversion therapy for unresectable hibitors and antiangiogenic targeted drugs for advanced
hepatocellular carcinoma：a single ⁃ arm，multicentre， hepatocellular carcinoma（2024 edition）［J］. Biosci Trends，
prospective study［J］. EClinicalMedicine，2024，67： 2025，18（6）：505-524
102367 ［28］WU J Y，ZHANG Z B，ZHOU J Y，et al. Outcomes of sal⁃
［20］ZHANG H L，YANG T S，HUANG L P，et al. Tumor re⁃ vage surgery for initially unresectable hepatocellular car⁃
gression grade predicts recurrence⁃free survival in inter⁃ cinoma converted by transcatheter arterial chemoemboli⁃
mediate⁃advanced hepatocellular carcinoma after conver⁃ zation combined with lenvatinib plus anti⁃PD⁃1 antibod⁃
sion therapy［J］. Front Immunol，2025，16：1704239 ies：a multicenter retrospective study［J］. Liver Cancer，
［21］XIAO R，YANG Z Y，ZHENG Z H，et al. Survival out⁃ 2023，12（3）：229-237
comes，recurrence patterns，and its corresponding thera⁃ ［29］KIKUCHI T，TAKEUCHI Y，NOUSO K，et al. Predictive
peutic management after conversion therapy followed by factors for transition to conversion therapy in hepatocellu⁃
curative resection for hepatocellular carcinoma：a real ⁃ lar carcinoma using atezolizumab plus bevacizumab［J］.
world study［J/OL］. Liver Cancer，2026. https：//karger. Liver Int，2024，44（6）：1456-1463
com/lic/article/doi/10.1159/000550954/945178. DOI：10. ［30］CHEN L J，ZHANG R G，LIN Z Y，et al. Radiation thera⁃
1159/000550954 py in the era of immune treatment for hepatocellular carci⁃
［22］HE T，XU B，YANG Z Y，et al. Stable disease without tu⁃ noma［J］. Front Immunol，2023，14：1100079
mor shrink cannot benefit from surgery following immune⁃ ［31］SONG T Q，LANG M R，REN S H，et al. The past，present
based therapy in potentially resectable hepatocellular car⁃ and future of conversion therapy for liver cancer［J］. Am J
cinoma［J/OL］. Liver Cancer，2026. https：//karger.com/ar⁃ Cancer Res，2021，11（10）：4711-4724
ticle/doi/10.1159/000550497. DOI：10.1159/000550497 ［32］曹俊宁，张雯雯，赵海涛，等. 基于免疫联合靶向方案的
［23］LU S C，ZHANG W W，LI J F，et al. Sintilimab（PD⁃1 in⁃ 晚期肝细胞癌转化治疗中国专家共识（2021版）［J］. 肝
hibitor）plus lenvatinib as conversion therapy followed by 癌电子杂志，2021，8（2）：6-15
sequential surgery（SILENSES）for advanced unresectable SUN H C，ZHOU J，WANG Z，et al. Chinese expert con⁃
hepatocellular carcinoma：a phase Ⅱ，expansion trial［J］. sensus on conversion therapy for hepatocellular carcinoma
Sig Transduct Target Ther，2026，11：167 （2021 edition）［J］. Electronic Journal of Liver Tumor，
［24］YANG D L，PENG N，NONG J L，et al. Survival benefit of 2021，8（2）：6-15
hepatectomy after complete or partial response to conver⁃ （收稿：2026-04-28；修回：2026-05-30；录用：2026-06-10）
sion therapy in unresectable hepatocellular carcinoma （本文编辑：陈汐敏）